Biologics Market Size, Share Global Analysis Report, 2023 – 2030

Industry Insights

[185+ Pages Report] According to the report published by Facts and Factors, the global Biologics market size was valued around USD 375 billion in 2022 and is predicted to expand to around USD 675 billion by 2030 with a compound annual growth rate (CAGR) of approximately 8.76% between 2023 and 2030. The report analyses the global Biologics market drivers, restraints/challenges, and the effect they have on the demands during the forecast period. In addition, the report analyses emerging opportunities in the Biologics market.

This professional and specialized report study examines the technical and business perspective of the biologics industry. The report provides a historical analysis of the industry as well as the projected trends expected to be witnessed in the biologics market. The report study analyzes the market statistics at the global as well as the regional levels to gain an in-depth perspective of the overall biologics market. The historical insights are provided from 2019 to 2021 and projected trends are provided from 2023 to 2030. The quantitative data is provided in terms of value (USD Million) for 2020 – 2030. The qualitative data is reinforced by analyzing and providing numerous market dynamics (directly or indirectly affecting the industry) such as growth drivers, restraints, challenges, and opportunities.

Key Insights from Primary Research

• According to interview with industry participants, the biologics market is anticipated to expand at a significant rate over the forecast period i.e. a compound annual growth rate of around 9.1% by 2026 end over 2019 in terms of market value
• In terms of type segmentation, monoclonal antibodies segment has the dominant share in the global market
• Among source segmentation, microbial segment stands at first position on the basis of market share
• Eli Lilly & Company, Johnson & Johnson Services Inc., Addgene, Merck & Co. Inc., Abbvie Inc., Sanofi, Novo Nordisk A/S, Amgen, Pfizer Inc., Celltrion, Samsung Biologics, and F Hoffman La Roche are some of the prominent players of biologics market across the globe

Key Recommendations from Analysts

• As per our analyst, top 10 manufacturers of the biologics market accounts for dominant revenue share in the global market
• In-house manufacturing has dominant share in the global biologics market and will continue to do so over the forecast period
• Biological drugs are highly dependent and sensitive on the conditions in which they are handled and manufactured is the main factor restraining the global market over the forecast period

In terms of sales value, the global biologics market is anticipated to grow at around 9% over the forecast period

We have included various industry analysis models in our report and extensively demonstrated the key business strategies and competitive landscape of the biologics market in our study. Our study also includes an analysis of Porter’s Five Forces framework for understanding the competitive strategies adopted by various stakeholders involved in the entire value chain of the Biologics market.

The report also offers an in-depth analysis of the market shares of each industry player and gives an outline of the market position of key players in the biologics market. Moreover, the study offers wide coverage of key strategic advances witnessed in the market such as new product launches, acquisitions & mergers, collaborations & joint ventures, funding & VC activities, agreements, partnerships, R&D activities, and regional expansion of key players of the biologics market.

Report Scope

The research study provides a critical assessment of the biologics industry by logically segmenting the market on the basis of type, source, disease category, manufacturing, and regions. Based on the past, present, and future trends, all the segments were analyzed from the bottom up, and the market sizes have been estimated from 2020 to 2026.

Technological advances increase in healthcare, reimbursement of biologics, ability to command high prices, growing mergers and acquisitions, rising biologics in the pipeline, etc. are few of the microeconomic factors affecting the positive growth of the biologics market within the forecast period. Moreover, some of the macroeconomic factors responsible for the growth of the global market include aging government initiatives, population, growing GDP across multiple emerging economies, etc.

However, factors hindering the global biologics market include manufacturing biologics from regulators, higher supervision during clinical trials, and pricing pressure. Furthermore, the rise of biosimilars is the major factor restraining the biologics market across the globe.

The biologics market is segmented based on type, source, disease category, and manufacturing. Based on type segmentation, the market is classified into monoclonal antibodies, vaccines, recombinant proteins, antisense, RNAi, & molecular therapy, and others. The global biologics market is segmented by source analysis into microbial, mammalian, and others. Based on the disease category, the biologics market is classified as oncology, infectious diseases, immunological disorders, cardiovascular disorders, hematological disorders, and others. In the end, the biologics market analysis is split into major manufacturing category including in-house and outsourced.

On the basis of geography, the global biologics market is divided into major five regions like Asia Pacific, Europe, North America, Latin America, and the Middle East, and Africa. Among the aforementioned regions, the Asia Pacific biologics market is anticipated to expand at a significant growth rate over the forecast period.

Key players operating in the biologics industry are 

• F Hoffman La Roche
• Samsung Biologics
• Celltrion
• Pfizer Inc.
• Amgen
• Novo Nordisk A/S
• Sanofi
• Abbvie Inc.
• Merck & Co. Inc.
• Addgene
• Johnson & Johnson Services Inc.
• Eli Lilly & Company

The detailed description of players includes parameters such as financial overview, business strategy, key developments, and company overview of the company.

This report segments the Global Biologics market as follows:

By Type Analysis

• ·Monoclonal Antibodies
• ·Vaccines
• ·Recombinant Proteins
• ·Antisense, RNAi, & Molecular Therapy
• ·Others

By Source Analysis

• ·Microbial
• ·Mammalian
• ·Others

By Disease Category Analysis

• ·Oncology
• ·Infectious Diseases
• ·Immunological Disorders
• ·Cardiovascular Disorders
• ·Hematological Disorders
• ·Others

By Manufacturing Analysis

• ·In-house
• ·Outsourced

By Region

North America

• U.S
• Canada

Europe

• Germany
• France
• The U.K.
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• South Korea
• South-East Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

KEY BUSINESS POINTERS ADDRESSED & FOREMOST REASONS TO PROCURE THE REPORT:

• Statistical Analysis of the Past, Current, and Future Trends of the Industry with Validated Market Sizes Data

• Direct and Indirect Rationales Impacting the Industry

• In-depth and Micro Analysis of Viable Segments and Sub-segments

• Companies and Vendors Market Share, Competitive Landscape, and Player Positioning Analysis

• Demand Side (Consumption) and Supply Side (Production) Perspective and Analysis wherever applicable

• Key Buyers and End-Users Analysis

• Value Chain and Manufacturing Cost Structure Analysis wherever relevant

• Key Marketing Strategies as well as Key Sales Channels adopted in the market

• Investment Opportunity Analysis & Patents Analysis wherever feasible

• Technological Road Map & Technical Analysis

• Robust Research Methodology comprising dynamic mix (65%~35%) of Extensive Primary Research (primary interviews, ad-hoc surveys, questionnaires) and Protracted Secondary Research (proprietary in-house database, paid external databases, publically available validated sources)